How does Dr Bianchi describe the efficacy of BCMA-targeted bispecific antibodies, such as elranatamab and teclistamab, in AL amyloidosis?
Responses in about half of patients, typically developing over several months, with partial reductions in light-chain levels
Near-universal responses that are very rapid, occurring within weeks, and profound, with light chains often becoming undetectable in the blood
Deep responses, but toxicity so high that use is restricted to fit patients without cardiac involvement